Skip to main content
CANbridge Pharmaceuticals Inc. logo

CANbridge Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · 1228 LEI · 8755009KKZM9ETBOF853 HKEX Manufacturing
Open in API
Filings indexed 190 across all filing types
Latest filing 2025-09-30 Interim / Quarterly Rep…
Country KY Cayman Islands
Listing HKEX 1228

About CANbridge Pharmaceuticals Inc.

http://www.canbridgepharma.com

CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of transformative therapies for rare diseases and rare genetic conditions. The company leverages its foundation in China to deliver life-changing therapeutics globally. Its commercial portfolio includes approved products such as Hunterase® (a recombinant human Enzyme Replacement Therapy) and Livmarli (an oral inhibitor of the ileal bile acid transporter). CANbridge also maintains a pipeline of investigational therapies, including gene therapies, targeting high-impact indications in rare genetic diseases.

Recent filings

Filing Released Lang Actions
INTERIM REPORT 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report 2025' for CANbridge Pharmaceuticals Inc. It contains comprehensive financial statements, including the 'Interim Condensed Consolidated Statement of Profit or Loss', 'Statement of Financial Position', 'Statement of Changes in Equity', and 'Statement of Cash Flows', as well as management discussion and analysis for the six months ended June 30, 2025. This fits the definition of an Interim/Quarterly Report (IR). H1 2025
2025-09-30 English
COMPLETION OF SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE
Share Issue/Capital Change Classification · 1% confidence The document is an official Hong Kong Stock Exchange announcement by CANbridge Pharmaceuticals announcing the completion of subscriptions of new shares under a general mandate, detailing the number of shares issued, subscription price, proceeds raised, and changes in shareholding structure. This constitutes a new share issuance/capital change announcement. Therefore, it should be classified as a Share Issue/Capital Change filing.
2025-09-28 English
SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement filed on the Hong Kong Stock Exchange regarding the conditional subscription agreements to issue 9,996,196 new shares under a general mandate. It provides share subscription terms, pricing, conditions precedent, application for listing, use of proceeds, and the effect on shareholding structure. There is no detailed financial statement as in an annual or interim report, nor is it a dividend notice or corporate governance statement. This is a capital-raising transaction involving issuance of new shares, fitting the definition of Share Issue/Capital Change (SHA).
2025-09-15 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2025
Regulatory Filings Classification · 1% confidence The document is a routine Hong Kong Exchange Listing Rules "Monthly Return for Equity Issuer and Hong Kong Depositary Receipts" (Form FF301) detailing share capital and share movements for the month. It is a regulatory submission under HKEX Chapter 19B, not a narrative announcement of results, an earnings release, or an actual annual/interim report. It also does not fit more specific categories such as major shareholding notifications, director dealings, or proxy statements. As a standard listing rule filing without alternative classification, it falls under General Regulatory Filings (RNS).
2025-09-05 English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2024 ANNUAL REPORT
Regulatory Filings Classification · 1% confidence The document is a supplemental announcement relating to the 2024 Annual Report of a Hong Kong‐listed issuer, providing additional write‐off disclosures and share scheme details under the Listing Rules. It is not the Annual Report itself, nor an AGM presentation, earnings release, management discussion, or other defined category. It does not announce the publication timing of a report (so not RPA) and falls into the catch‐all “Regulatory Filings” category for miscellaneous announcements under the Listing Rules.
2025-09-03 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025' for CANbridge Pharmaceuticals Inc. It contains comprehensive unaudited condensed consolidated financial statements, including the statement of profit or loss, statement of financial position, and notes to the financial statements for the interim period. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2025
2025-08-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.